Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole.
Phase of Trial: Phase IV
Latest Information Update: 10 Jan 2014
At a glance
- Drugs Aripiprazole (Primary)
- Indications Mood disorders; Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- 21 Jun 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2010 Company added as trial sponsor as reported by ClinicalTrials.gov.